ArticleThe Journal of antimicrobial chemotherapy2026
Characterization of the intrinsic AmpC β-lactamase of Escherichia marmotae and its impact on decreased susceptibility to cefiderocol and resistance to broad-spectrum cephalosporins.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesWe aimed to characterize the intrinsic AmpC β-lactamase (EMC-2) from an Escherichia marmotae clinical isolate recovered from a bloodstream infection, exhibiting resistance to broad-spectrum cephalosporins.
methodsCloning experiments in Escherichia coli were performed to evaluate the impact of the respective AmpC enzymes on β-lactam susceptibility. Purification of the enzymes was performed by ion-exchange chromatography, and kinetic assays were performed by UV spectrophotometry.
resultsBy comparing the sequence of this AmpC with that of a WT E. marmotae, four amino acid substitutions and one amino acid deletion at position 296 were identified. Furthermore, a promoter alteration was responsible for an enhanced gene expression. Production of EMC-2 in E. coli TOP10 conferred an extended-spectrum AmpC (ESAC) phenotype characterized by increased MICs of cefotaxime, cefepime and cefiderocol. Site-directed mutagenesis confirmed the important role of the Arg296 deletion in this phenotype.
conclusionsWe showed that the intrinsic AmpC of E. marmotae can acquire both structural and regulatory modifications that broaden its substrate spectrum, leading to reduced susceptibility to clinically relevant β-lactams, including cefiderocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.